Pfizer Gestione

Gestione criteri di controllo 3/4

Pfizer Il CEO è Albert Bourla, nominato in Jan2019, e ha un mandato di 5.83 anni. la retribuzione annua totale è $ 21.56M, composta da 8.3% di stipendio e 91.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.006% delle azioni della società, per un valore di € 8.49M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 7.8 anni.

Informazioni chiave

Albert Bourla

Amministratore delegato

US$21.6m

Compenso totale

Percentuale dello stipendio del CEO	8.3%
Mandato del CEO	5.8yrs
Proprietà del CEO	0.006%
Durata media del management	5.8yrs
Durata media del Consiglio di amministrazione	7.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Albert Bourla rispetto agli utili di Pfizer?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$4b
Jun 30 2024	n/a	n/a	-US$3b
Mar 31 2024	n/a	n/a	-US$288m
Dec 31 2023	US$22m	US$2m	US$2b
Oct 01 2023	n/a	n/a	US$10b
Jul 02 2023	n/a	n/a	US$21b
Apr 02 2023	n/a	n/a	US$29b
Dec 31 2022	US$33m	US$2m	US$31b
Oct 02 2022	n/a	n/a	US$30b
Jul 03 2022	n/a	n/a	US$29b
Apr 03 2022	n/a	n/a	US$25b
Dec 31 2021	US$24m	US$2m	US$22b
Oct 03 2021	n/a	n/a	US$19b
Jul 04 2021	n/a	n/a	US$12b
Apr 04 2021	n/a	n/a	US$9b
Dec 31 2020	US$21m	US$2m	US$7b
Sep 27 2020	n/a	n/a	US$212m
Jun 28 2020	n/a	n/a	US$7b
Mar 29 2020	n/a	n/a	US$9b
Dec 31 2019	US$18m	US$2m	US$11b
Sep 29 2019	n/a	n/a	US$16b
Jun 30 2019	n/a	n/a	US$13b
Mar 31 2019	n/a	n/a	US$11b
Dec 31 2018	US$10m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$24b
Jul 01 2018	n/a	n/a	US$23b
Apr 01 2018	n/a	n/a	US$22b
Dec 31 2017	US$9m	US$1m	US$21b

Compensazione vs Mercato: La retribuzione totale di Albert ($USD 21.56M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 5.83M ).

Compensazione vs guadagni: La retribuzione di Albert è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Albert Bourla (62 yo)

5.8yrs

Mandato

US$21,562,064

Compensazione

Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and serves as its Chairman and director of the Board since January 2020 and had been its Executive D...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Albert Bourla	Chairman of the Board & CEO	5.8yrs	US$21.56m	0.0059% € 8.5m
David Denton	Chief Financial Officer & Executive VP	2.5yrs	US$5.28m	0.00067% € 968.8k
Mikael Dolsten	Chief Scientific Officer and President of Research & Development	5.8yrs	US$8.86m	0.0057% € 8.3m
Douglas Lankler	Executive VP & General Counsel	10.9yrs	US$5.48m	0.0026% € 3.8m
Jennifer Damico	Senior VP	4.7yrs	Nessun dato	0.00015% € 216.9k
Lidia Fonseca	Executive VP and Chief Digital & Technology Officer	5.8yrs	Nessun dato	0.00063% € 911.0k
Francesca DeMartino	Chief Investor Relations Officer	no data	Nessun dato	Nessun dato
Rady Johnson	Executive VP and Chief Compliance	10.9yrs	Nessun dato	0.0018% € 2.6m
Andreas Panayiotou	Global Chief Marketing Officer	2.2yrs	Nessun dato	Nessun dato
Payal Becher	Chief People Experience Officer & Executive VP	4.4yrs	Nessun dato	0.00063% € 911.0k
Sally Susman	Executive VP & Chief Corporate Affairs Officer	16.8yrs	Nessun dato	0.0029% € 4.1m
Annette Doherty	Head of Worldwide Pharmaceutical Sciences	19.5yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di PFED è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Albert Bourla	Chairman of the Board & CEO	4.8yrs	US$21.56m	0.0059% € 8.5m
Shantanu Narayen	Lead Independent Director	11.2yrs	US$430.00k	Nessun dato
Ronald Blaylock	Independent Director	7.8yrs	US$380.00k	0.00023% € 332.6k
Suzanne Nora Johnson	Independent Director	17.2yrs	US$410.00k	0.00018% € 260.3k
James Smith	Independent Director	10.4yrs	US$390.00k	0.000060% € 86.8k
Charles Hagel	Member of Emerging Markets Advisory Board	no data	Nessun dato	Nessun dato
Susan Hockfield	Independent Director	4.7yrs	US$363.00k	Nessun dato
Daniel Littman	Independent Director	6.7yrs	US$391.40k	Nessun dato
James Robert Quincey	Independent Director	4.8yrs	US$380.00k	Nessun dato
Scott Gottlieb	Independent Director	5.4yrs	US$417.20k	0.00018% € 260.3k
Joseph Echevarria	Independent Director	9.4yrs	US$390.00k	Nessun dato
Helen Hobbs	Independent Director	12.9yrs	US$410.00k	Nessun dato

7.8yrs

Durata media

65.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PFED sono considerati esperti (durata media dell'incarico 7.8 anni).

Pfizer Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Recent updates

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Pfizer Inc. Announces Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

U.S. FDA Approves Pfizer Inc.’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer Inc. Announces Positive Topline Results from the Final Prespecified Overall Survival Analysis of the TALAPRO-2 Study of TALZENNA®

Starboard Value Wants Pfizer to Make Changes to Turn its Performance Around

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Pfizer Inc. to Report Q3, 2024 Results on Oct 29, 2024

Pfizer Announces its BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Pfizer Inc. Launches PfizerForAll

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Pfizer Inc Announces Results of ABRYSVO® for RSV in Immunocompromised Adults

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

Pfizer Inc. Revises Earnings Guidance for the Year 2024

European Commission Approves Pfizer's DURVEQTIX (Fidanacogene Elaparvovec), A One-Time Gene Therapy for Adults with Hemophilia B

Pfizer Inc. Announces Positive Topline Results from Phase 3 Study of Hemophilia A Gene Therapy Candidate

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media